Legal & General Group Plc Boosts Stock Holdings in Artivion, Inc. $AORT

Legal & General Group Plc grew its position in shares of Artivion, Inc. (NYSE:AORT) by 37.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 190,748 shares of the company’s stock after purchasing an additional 51,704 shares during the quarter. Legal & General Group Plc owned approximately 0.40% of Artivion worth $8,700,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. SG Americas Securities LLC grew its stake in Artivion by 578.4% in the 4th quarter. SG Americas Securities LLC now owns 39,030 shares of the company’s stock valued at $1,780,000 after acquiring an additional 33,277 shares during the period. Public Sector Pension Investment Board grew its stake in Artivion by 23.7% in the 3rd quarter. Public Sector Pension Investment Board now owns 161,970 shares of the company’s stock valued at $6,858,000 after acquiring an additional 30,989 shares during the period. JPMorgan Chase & Co. grew its stake in Artivion by 338.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 122,199 shares of the company’s stock valued at $5,174,000 after acquiring an additional 94,312 shares during the period. Vanguard Group Inc. grew its stake in Artivion by 4.7% in the 4th quarter. Vanguard Group Inc. now owns 3,170,089 shares of the company’s stock valued at $144,588,000 after acquiring an additional 141,030 shares during the period. Finally, Kennedy Capital Management LLC grew its stake in Artivion by 19.0% in the 3rd quarter. Kennedy Capital Management LLC now owns 437,792 shares of the company’s stock valued at $18,536,000 after acquiring an additional 70,030 shares during the period. 86.37% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. Needham & Company LLC dropped their price target on shares of Artivion from $58.00 to $44.00 and set a “buy” rating on the stock in a research note on Friday, May 8th. Citizens Jmp lowered their target price on shares of Artivion from $53.00 to $48.00 and set a “market outperform” rating on the stock in a research note on Friday, May 8th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Artivion in a research note on Wednesday, May 20th. Canaccord Genuity Group lowered their target price on shares of Artivion from $51.00 to $48.00 and set a “buy” rating on the stock in a research note on Friday, February 13th. Finally, Stifel Nicolaus set a $45.00 target price on shares of Artivion in a research note on Monday. Seven analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $46.17.

Artivion Stock Up 1.1%

NYSE AORT opened at $20.80 on Friday. Artivion, Inc. has a 52 week low of $19.16 and a 52 week high of $48.25. The company has a quick ratio of 2.80, a current ratio of 3.86 and a debt-to-equity ratio of 0.48. The business’s fifty day simple moving average is $30.74 and its 200-day simple moving average is $38.01. The firm has a market cap of $1.01 billion, a PE ratio of 86.68 and a beta of 1.26.

Artivion Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.